Idiopathic Pulmonary Fibrosis Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
InterMune Plans Pirfenidone Pulmonary Fibrosis Phase III Study In 2006
InterMune's pivotal trials of pirfenidone will be the first Phase III studies of an idiopathic pulmonary fibrosis drug to use the primary endpoint of lung function as measured by change in forced vital capacity
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011